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Introduction {#sec001}
============

Precise measurement of plasma parameters is not only important for accurate diagnosis, but also provides a non-invasive, easily applicable tool to monitor disease progression and to possibly predict clinical outcome \[[@pone.0188921.ref001]\]. Moreover, most clinical studies include plasma parameters in their study design and billions of plasma samples are stored within biobanks for further analysis \[[@pone.0188921.ref002], [@pone.0188921.ref003]\].

During the past few years, platelets and microvesicles have been identified as an important source of mediators, modulating numerous pathways, not only in coagulation, but also in angiogenesis, wound healing, and immune diseases \[[@pone.0188921.ref004]--[@pone.0188921.ref008]\]. Upon platelet activation, a plethora of molecules is released from intracellular granules, including TSP-1, PF4, vascular endothelial growth factor (VEGF), serotonin, and CD62P \[[@pone.0188921.ref009]\]. As platelet granules store over 300 different molecules, degranulation has to be a precisely coordinated process, adjusted to the specific physiological needs \[[@pone.0188921.ref010], [@pone.0188921.ref011]\]. This is not only assured by distinct granule types (α-granule, dense granule, and lysosomes), but also *via* diverse packaging and agonist-dependent release of granule subtypes \[[@pone.0188921.ref007]\]. Moreover, since platelets store molecules with opposing functions (e.g. pro- and antiangiogenic; pro-and anti-inflammatory) time-dependent platelet secretion profiles have been considered important for clinical outcome \[[@pone.0188921.ref012]\]. However, due to the high sensitivity of platelets and their quick adaption to changes in the microenvironment, they are prone to *in vitro* activation, which has to be considered when preparing plasma for analysis of platelet-derived mediators. Therefore, prevention of platelet activation and complete removal of platelets is equally important for plasma preparation as preserving protein stability and enzyme activity of plasma components.

While this has been known for decades, there is still enormous discrepancy between published plasma levels of platelet-stored molecules, ranging over several orders of magnitude \[[@pone.0188921.ref013]\]. This broad variation makes it difficult to compare different studies and leads to highly controversial findings.

Therefore, optimized plasma preparation is crucial to measure differences in platelet granule release and to avoid artifacts due to *in vitro* platelet activation, which would mask biological differences that occurred *in vivo*. Moreover, appropriate plasma preparation helps to reduce sample variations and increases the reproducibility of results.

To address this issue, we compared different plasma preparation protocols with special emphasis on appropriate anticoagulants as well as storage temperature to avoid *in vitro* platelet activation, additionally considering time between blood drawing and sample processing.

Methods {#sec002}
=======

Study collective of healthy volunteers {#sec003}
--------------------------------------

All healthy volunteers (5 male, 3 female donors aged between 26--51 years) were free of any medication for at least 2 weeks and gave their informed consent. Venous blood was collected from the antecubital vein using a 24G needle and the indicated tubes for anticoagulation. The study was approved by the Human Ethics Committee of the Medical University of Vienna (EK237/2004) and complied with the Declaration of Helsinki.

Plasma preparation {#sec004}
------------------

Depending on the experimental set-up for plasma preparation (see [Fig 1](#pone.0188921.g001){ref-type="fig"}), blood was drawn into pre-chilled or room temperature (RT) citrate-theophylline-adenosine-dipyridamole (CTAD), acid-citrate-dextrose (ACD), 3.8% citrate, dipotassium ethylenediaminetetraacetic acid (EDTA) or sodium heparin tubes. Blood samples were centrifuged at the indicated time-points at 1,000 x g and 4°C for 10 min. After this first centrifugation step, the plasma supernatant was transferred to a new vial and subjected to a second round of centrifugation at 10,000 x g and 4°C for 10 min to guarantee removal of all cellular components. Samples labeled as 4°C were always kept on ice, while RT indicates that samples were not cooled between centrifugation steps. The supernatant was stored in aliquots at -80°C until further use.

![Experimental set-up to compare the effect of different anticoagulants on plasma levels of platelet-stored factors.\
(A) Plasma preparation. Anticoagulated blood of 8 healthy volunteers was centrifuged at 1,000 x g and 4°C for 10 minutes. Supernatants were transferred to new tubes and centrifuged at 10,000 x g and 4°C for 10 minutes to generate platelet-free plasma. Supernatants of the second centrifugation step were aliquoted and stored at --80°C until further use. (B) Sampling. Blood of each donor was collected using CTAD (blue), ACD (pink), citrate (green), EDTA (red) and heparin (yellow) as anticoagulant. Half of the samples were kept either at 4°C or at room temperature. Plasma was generated at 0.5 h, 2 h, 6 h, and 24 h. To analyze the effect of *in vitro* platelet activation a subgroup of samples was stimulated with thrombin at a submaximal concentration and plasma was generated after 0.5 h and 6 h.](pone.0188921.g001){#pone.0188921.g001}

*In vitro* activation of platelets {#sec005}
----------------------------------

Within 30 minutes after blood drawing, platelets were stimulated in whole blood with a submaximal dose of thrombin (0.1 U/mL) to trigger platelet activation *in vitro*.

Determination of plasma concentrations {#sec006}
--------------------------------------

Plasma concentrations of TSP-1, PF4, and sCD62P were analyzed with enzyme-linked immunosorbent assay (ELISA) using commercially available ELISA kits (Quantikine; R&D Systems, Minneapolis, MN, U.S.A.) according to the manufacturer´s instructions.

Statistical analysis {#sec007}
--------------------

Data are presented as medians with interquartile ranges and were analyzed with Graph Pad Prism 6 using one-way and two-way ANOVA with a Dunnet correction. \* p values \< 0.05 were considered as statistically significant.

Results {#sec008}
=======

Plasma levels of platelet-stored factors are substantially increased after non-optimized plasma preparation and highly sensitive to temperature variations {#sec009}
----------------------------------------------------------------------------------------------------------------------------------------------------------

To test for the effect of different anticoagulants on the level of platelet-stored molecules, we compared different anticoagulants in pre-chilled vials (Figs [1](#pone.0188921.g001){ref-type="fig"}, [2A and 2B](#pone.0188921.g002){ref-type="fig"}, [Table 1](#pone.0188921.t001){ref-type="table"}).

![Plasma levels of platelet-stored factors vary among different anticoagulants.\
Plasma levels of PF4 (A, C) and TSP-1 (B, D) were determined in 8 healthy individuals. Plasma was prepared from CTAD (black bar), ACD (dark grey bar), citrate (grey bar), heparin (white bar) or EDTA (patterned bar) blood at 4°C (A-B) or at room temperature (C-D) within 30 min after blood draw. Plasma concentration was measured using ELISA. Significant differences were analyzed using one-way ANOVA with Dunnett correction and were depicted as \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 (in comparison to CTAD).](pone.0188921.g002){#pone.0188921.g002}

10.1371/journal.pone.0188921.t001

![](pone.0188921.t001){#pone.0188921.t001g}

             PF4 (ng/mL)     TSP-1 (ng/mL)                     
  ---------- --------------- --------------- ----------------- ----------
  **4°C**                                                      
   CTAD      12 (4--36)                      25 (0--144)       
   ACD       7 (4--10)       0.9999          31 (9--56)        0.9999
   Citrate   12 (3--35)      0.9999          35 (2--234)       0.9982
   Heparin   149 (48--198)   0.0090          514 (76--1228)    0.0013
   EDTA      106 (10--428)   0.0032          254 (7--1025)     0.0484
  **RT**                                                       
   CTAD      17 (5--30)                      33 (1--142)       
   ACD       10 (8--21)      0.9999          47 (18--85)       \>0.9999
   Citrate   87 (28--152)    0.5215          152 (19--899)     0.8733
   Heparin   94 (15--172)    0.5309          444 (77--1326)    0.4996
   EDTA      269 (51--814)   \<0.0001        886 (306--4258)   0.0003

Plasma PF4 and TSP-1 levels showed a significant correlation with different anticoagulants (p = 0.0003 for PF4 and p = 0.0003 for TSP-1). Whereas plasma levels of PF4 and TSP-1 were comparable between CTAD, ACD and citrate plasma, these proteins substantially increased when heparin or EDTA were used as an anticoagulant ([Fig 2A and 2B](#pone.0188921.g002){ref-type="fig"}). Moreover, this was associated with an augmented inter-individual variation within the samples collected from EDTA plasma. Plasma levels of sCD62P were comparable between all four different groups ([S1 Fig](#pone.0188921.s001){ref-type="supplementary-material"}). When we further assessed platelet-stored molecules in different anticoagulants after processing at RT to evaluate the impact of temperature on *in vitro* platelet activation, the effect was even more pronounced (p\<0.0001 for PF4; [Fig 2C](#pone.0188921.g002){ref-type="fig"}). In particular, we found elevated levels of PF4 and TSP-1 in non-CTAD preparations such as citrate, heparin, and EDTA plasma compared to plasma processed at 4°C ([Fig 2C and 2D](#pone.0188921.g002){ref-type="fig"}). In citrate plasma, PF4 and TSP-1 levels were increased 5.1-fold and 4.6-fold, respectively. Importantly, CTAD and ACD were the only anticoagulants that were not affected by changing processing temperature from 4°C to room temperature, as evidenced by a similar level of PF4 and TSP-1 under both conditions. No substantial fluctuations were observed for sCD62P concentrations ([S1 Fig](#pone.0188921.s001){ref-type="supplementary-material"}).

Storage time-dependent differences in plasma levels of platelet-stored factors due to anticoagulants {#sec010}
----------------------------------------------------------------------------------------------------

As plasma preparation is not always feasible immediately after blood drawing under clinical conditions, we tested the effect of storage on the release of platelet contents either at 4°C or at room temperature using different anticoagulants ([Fig 3](#pone.0188921.g003){ref-type="fig"}, [Table 2](#pone.0188921.t002){ref-type="table"}). Both time and anticoagulant had a highly significant effect on the plasma levels of PF4 and TSP-1 (p\<0.0001 for time and anticoagulants). Even though heparin and EDTA plasma showed already high levels of PF4 and TSP-1 under optimal timing conditions (within 30 minutes after blood drawing---see above), storage times between 2 hours and 24 hours resulted in a continuous increase in plasma levels, peaking at a concentration of 592 ng/mL and 3765 ng/mL as well as 595 ng/mL and 2752 ng/mL for PF4 and TSP-1, respectively ([Fig 3A and 3B](#pone.0188921.g003){ref-type="fig"}). In contrast, CTAD and ACD plasma levels of PF4 as well as TSP-1 remained constantly low even over a time period of 6 hours and only showed a moderate increase after 24 hours. Consistent with this finding, CTAD and ACD plasma exerted the smallest variation between different blood donors. At 4°C, we could neither observe any time-depended effects on plasma levels of sCD62P nor due to usage of certain anticoagulants ([S2 Fig](#pone.0188921.s002){ref-type="supplementary-material"}). Furthermore, we monitored time-dependent changes due to storage at room temperature and found a comparable increase in plasma levels of PF4 and TSP-1 in citrate, heparin, and EDTA plasma pointing to maximal granule release even under conditions of optimal cooling, which could not further be augmented due to storage at room temperature ([Fig 3C and 3D](#pone.0188921.g003){ref-type="fig"}). The only exceptions were CTAD and ACD plasma, in which we could only observe a moderate increase in PF4 levels over a time period of 6 hours (median 69 ng/mL and 88 ng/mL). However, CTAD was not able to prevent granule release after 24 hours at room temperature, pointing to the absolute limits of anticoagulation (median 225 ng/mL). In contrast to the other anticoagulants, plasma levels of TSP-1 remained relatively low in CTAD and ACD plasma over the whole experimental period.

![Time-dependent differences in plasma levels of platelet-stored factors.\
Blood from 8 healthy donors was anticoagulated with CTAD (black bar), ACD (dark grey bar), citrate (grey bar), heparin (white bar) or EDTA (patterned bar) and stored at 4°C (A-B) or at room temperature (C-D) for 0.5 h, 2 h, 6 h or 24 h until plasma preparation. Concentrations of PF4 (A, C) and TSP-1 (B, D) were determined for each time point. Significant differences were analyzed using two-way ANOVA with Dunnett correction (with CTAD as reference) and were depicted as \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, and \*\*\*\*p\<0.0001.](pone.0188921.g003){#pone.0188921.g003}

10.1371/journal.pone.0188921.t002

![](pone.0188921.t002){#pone.0188921.t002g}

                   PF4 (ng/mL)        TSP-1 (ng/mL)                        
  ---------------- ------------------ --------------- -------------------- ----------
  **0.5 h, 4°C**                                                           
   CTAD            12 (3--36)                         25 (0--144)          
   ACD             7 (4--10)          0.9998          31 (9--56)           \>0.9999
   Citrate         12 (4--35)         \>0.9999        35 (2--231)          \>0.9999
   Heparin         247 (39--198)      0.2001          514 (76--1228)       0.7431
   EDTA            106 (10--428)      0.1279          254 (7--1025)        0.9315
  **0.5 h, RT**                                                            
   CTAD            17 (5--30)                         33 (1--142)          
   ACD             10 (8--21)         \>0.9999        47 (18--85)          \>0.9999
   Citrate         87 (28--152)       0.8509          152 (19--899)        0.9853
   Heparin         94 (15--172)       0.8558          444 (77--1326)       0.8941
   EDTA            269 (51--814)      0.0077          886 (306--4258)      0.0632
  **2 h, 4°C**                                                             
   CTAD            16 (3--41)                         24 (9--229)          
   ACD             24 (9--47)         0.9998          31 (12--54)          \>0.9999
   Citrate         162 (6--415)       0.9888          86 (20--274)         0.9999
   Heparin         247 (39--415)      0.0032          1682 (284--3725)     0.0075
   EDTA            194 (50--359)      0.0501          840 (86--1852)       0.4880
  **2 h, RT**                                                              
   CTAD            55 (12--316)                       196 (50--572)        
   ACD             18 (3--77)         0.9930          79 (10--495)         0.9985
   Citrate         214 (51--316)      0.4575          667 (33--2084)       0.9583
   Heparin         119 (30--210)      0.5037          349 (14--3928)       0.4351
   EDTA            386 (36--727)      \<0.0001        2316 (400--8167)     0.0005
  **6 h, 4°C**                                                             
   CTAD            24 (4--76)                         42 (19--534)         
   ACD             17 (11--24)        0.9984          48 (0--78)           0.9998
   Citrate         49 (14--72)        0.0770          246 (28--424)        0.9986
   Heparin         290 (159--583)     0.0002          3765 (1658--8143)    \<0.0001
   EDTA            283 (149--853)     \<0.0001        1256 (107--2389)     0.2732
  **6 h, RT**                                                              
   CTAD            69 (24--162)                       197 (66--429)        
   ACD             88 (64--241)       0.9930          163 (84--4540)       0.8107
   Citrate         195 (102--355)     0.4575          417 (12--3194)       0.8107
   Heparin         166 (61--384)      0.5037          2181 (12--3194)      0.0083
   EDTA            467 (38--1492)     \<0.0001        2163 (754--7143)     0.0008
  **24 h, 4°C**                                                            
   CTAD            36 (9--83)                         208 (46--346)        
   ACD             65 (32--207)       0.8776          93 (2--186)          0.9990
   Citrate         274 (49--558)      0.0019          502 (17--1016)       0.9703
   Heparin         592 (102--838)     \<0.0001        2925 (620--11402)    \<0.0001
   EDTA            595 (281--1165)    \<0.0001        2752 (399--6954)     \<0.0001
  **24 h, RT**                                                             
   CTAD            225 (111--503)                     602 (117--1061)      
   ACD             199 (174--498)     0.9987          168 (12--1997)       0.9883
   Citrate         362 (193--575)     0.6141          1927 (142--4870)     0.2144
   Heparin         307 (105--609)     0.7573          1313 (185--5484)     0.1257
   EDTA            1026 (217--1499)   \<0.0001        5244 (2011--11360)   \<0.0001

For a quantification of the unwanted *in vitro* activation of platelets in comparison to plasma prepared with CTAD (30 min, 4°C), we calculated the fold-increase of the markers using the different other anticoagulants ([Fig 4](#pone.0188921.g004){ref-type="fig"}).

![Fold-increase of platelet-stored factors due to suboptimal plasma generation.\
Plasma concentrations of PF4 (A, C) and TSP-1 (B, D) were calculated as fold of plasma levels relative to CTAD plasma 30 min 4°C (8 healthy donors). Fold-increase is depicted for ACD (dark grey bar), citrate (grey bar), heparin (white bar) or EDTA (patterned bar) plasma at 0.5 h, 2 h, 6 h, and 24 h. Samples were either processed at 4°C (A-B) or at ambient temperature (C-D). Significant differences were analyzed using one-way ANOVA with Dunnett correction and were depicted as \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, and \*\*\*\*p\<0.0001 (in comparison to CTAD 30 min 4°C).](pone.0188921.g004){#pone.0188921.g004}

Anticoagulation with heparin and EDTA led to an increase in plasma levels of PF4 and TSP-1 even under conditions of immediate plasma preparation at 4°C ([Fig 4A and 4B](#pone.0188921.g004){ref-type="fig"}). Additionally, this effect increased even more after 2 hours and 6 hours in heparin and EDTA plasma. Citrate plasma showed comparable levels of PF4 and TSP-1 with CTAD plasma when processed at 4°C, however, after a time period of 24 hours the levels were increased 23-fold and 20-fold in comparison to optimized CTAD plasma preparation, respectively.

At room temperate, pronounced increases were already observed at 30 minutes with an 6-35-fold increase of PF4 and TSP-1 levels in citrate, heparin, and EDTA plasma ([Fig 4C and 4D](#pone.0188921.g004){ref-type="fig"}).

Plasma sCD62P levels were neither affected by anticoagulants, time or temperature ([S2 Fig](#pone.0188921.s002){ref-type="supplementary-material"}).

Effect of *in vitro* platelet activation on release of platelet stored factors {#sec011}
------------------------------------------------------------------------------

Since suboptimal plasma preparation apparently results in artificial platelet activation, we aimed to test the effect of anticoagulants on provoked platelet activation ([Fig 5](#pone.0188921.g005){ref-type="fig"}). Stimulation of anticoagulated blood with submaximal concentrations of thrombin caused a mild increase in plasma PF4 and TSP-1 levels within all anticoagulants. However, PF4 levels of CTAD and ACD plasma, even when stimulated with thrombin, were lower than in unstimulated citrate, heparin and EDTA plasma. The most pronounced rise after thrombin treatment was observed in EDTA plasma with 849 ng/mL and 2140 ng/mL for PF4 and TSP-1, respectively ([Fig 5A and 5B](#pone.0188921.g005){ref-type="fig"}).

![Effect of *in vitro* platelet activation on concentration of plasma factors.\
Blood of 8 healthy donors was anticoagulated with CTAD, ACD, citrate, heparin or EDTA (grey bar) and stimulated with the platelet activator thrombin (dark grey bar) at a submaximal dose for 0.5 h and 6 h at room temperature. Subsequently, plasma was prepared and analyzed for PF4 (A, C) and TSP-1 (B, D) levels. Significant differences were analyzed using two-way ANOVA with Bonferroni correction and were depicted as \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, and \*\*\*\*p\<0.0001 (in comparison to untreated).](pone.0188921.g005){#pone.0188921.g005}

Increasing incubation time from 30 minutes to 6 hours only caused a minor increase in TSP-1 levels, but led to a marked rise in PF4 levels ([Fig 5C and 5D](#pone.0188921.g005){ref-type="fig"}). Levels of sCD62P were not affected by thrombin treatment ([S3 Fig](#pone.0188921.s003){ref-type="supplementary-material"}).

Discussion {#sec012}
==========

Our results clearly illustrate the importance of using CTAD as anticoagulant for the generation of platelet-free plasma before measuring plasma markers of *in vivo* platelet activation. This was not only depicted by its consistently low levels of PF4 and TSP-1 even after storage over 24 hours, but also by its uniquely low variation between different plasma preparations. Anticoagulation with citrate, heparin, and EDTA is commonly used to measure concentrations of plasma factors in clinical settings \[[@pone.0188921.ref014]\]. However, we can clearly show that these suboptimal plasma preparation methods lead to a substantial degree of *in vitro* platelet granule release, which makes measurements prone to *in vitro* artefacts. Therefore, we want to raise scientific awareness for choosing the optimal anticoagulant, which is not only important for studies primarily focusing on platelets and coagulation, but also applies to a much broader spectrum of research as platelets store a plethora of heterogeneous proteins, affecting inflammation, angiogenesis, wound healing, and coagulation.

The preservative effect of CTAD can be explained by its various compounds: citrate, theophylline, adenosine, and dipyridamole \[[@pone.0188921.ref015]\]. Platelet activation is curtailed by endogenous levels of cyclic adenosine 3', 5'-monophosphate (cAMP) and cyclic guanosine-monophosphate (cGMP), which are kept high under physiological conditions due to release of nitric oxide and prostacyclin from the endothelium \[[@pone.0188921.ref016]\]. In blood processed in the presence of CTAD, this is achieved by adenosine, which stimulates adenylate cyclase, and by theophylline and dipyridamole, which inhibit phosphodiesterase-mediated cAMP degradation, thereby preventing *in vitro* activation of platelets \[[@pone.0188921.ref017]--[@pone.0188921.ref019]\]. Moreover, we could show that anticoagulation with ACD was similar effective as CTAD, which could be explained by the fact that ACD lowers the pH of blood to 6.5 thereby preventing platelet activation and aggregation \[[@pone.0188921.ref020]\].

Both citrate and EDTA chelate calcium, which is required for platelet activation and secondary hemostasis. A previous study suggested that EDTA may cross platelet plasma membranes to chelate intracellular calcium to prevent platelet activation \[[@pone.0188921.ref021]\]. However, our results demonstrate that *in vitro* platelet activation does occur in EDTA-anticoagulated blood as plasma levels of PF4 and TSP-1 were highest in EDTA plasma at 4°C and at room temperature. Of note, we could observe hemolysis in most of the plasma samples generated from EDTA blood, potentially affecting the quantification of certain plasma factors by colorimetric assays.

All three measured platelet factors, PF4, TSP-1, and sCD62P, are stored within α-granules, which is the largest and most abundant platelet granule type. The content of α-granules either arises from packaging within megakaryocytes or *via* uptake from the plasma by endocytosis, which makes platelets environmental sensors to changes in extracellular milieu \[[@pone.0188921.ref022]\] and an important surrogate marker for various disease. However, we could clearly demonstrate that α-granules are also prone to be released artificially due to suboptimal plasma preparation with EDTA or heparin blood, strengthening the importance of using proper anticoagulants, which not only prevents clotting, but also suppresses platelet activation and subsequent granule release. It is important to note that the standard deviation of biomarkers substantially increased in these suboptimal plasma preparations, suggesting that, even if all samples within a clinical trial were collected with the same sample preparation method, the degree of *in vitro* platelet activation during processing substantially varies between samples.

Moreover, our results clearly point out that storage temperature as well as time are additional factors affecting platelet activation, which has to be carefully considered during clinical monitoring of plasma concentrations of platelet granule contents. We provide evidence that blood anticoagulated with CTAD or ACD was able to provide the most robust and reproducible values, even when processed at ambient temperature or after storage for 6 hours, whereas anticoagulants such as heparin and EDTA led to a significant release of platelet granules. This is also reflected in studies showing that CTAD is preferable as an anticoagulant for flow cytometric measurement of platelet activation \[[@pone.0188921.ref023]--[@pone.0188921.ref025]\].

Furthermore, we did not only study the effect of time and temperature, but additionally challenged different anticoagulants by artificially activating platelets *in vitro* using a submaximal dose of the potent platelet activator thrombin. Thrombin is generated in small amounts e.g. by suboptimal blood drawing and therefore may lead to platelet activation *via* protease-activated receptor-1 (PAR-1) and PAR-4 \[[@pone.0188921.ref026]\]. Although thrombin caused a moderate rise of PF4 and TSP-1 levels in all plasma samples, levels of CTAD and ACD plasma still remained markedly low, underlining its robustness to artificial platelet activation during processing and therefore the importance of its usage in clinical settings.

In contrast to PF4 and TSP-1, we observed only moderate changes in sCD62P plasma content due to anticoagulants, time or temperature, with low sCD62P levels in all samples. CD62P is a transmembrane protein and as such a component of the α-granule membranes, which is exposed on the platelet surface upon activation. For release into the soluble phase of the plasma it requires cleavage and shedding from the membranes \[[@pone.0188921.ref027], [@pone.0188921.ref028]\], which might not occur under the conditions of plasma preparation that we used, explaining that hardly any changes could be detected. Therefore, sCD62P proved to be insufficient as plasma marker of *in vitro* platelet activation as α-granule release and proteolysis of CD62P from the surface of platelets clearly represent two distinct events.

Taken together, our data strongly suggest the use of on optimized plasma preparation using CTAD or ACD anticoagulated blood for the detection of platelet-derived plasma factors, since suboptimal plasma preparation leads to artificial *in vitro* platelet activation, which might ultimately mask biologically relevant differences within translational research studies.

Supporting information {#sec013}
======================

###### Plasma levels of sCD62P do not vary among different anticoagulants.

Plasma levels of CD62P (A, B) were determined in 8 healthy individuals. Plasma was prepared from CTAD (black bar), citrate (dark grey bar), heparin (grey bar) or EDTA (white bar) blood at 4°C (A) or at room temperature (B) within 30 min after blood draw. Plasma concentration was measured using ELISA. Significant differences were analyzed using one-way ANOVA with Dunnett correction.

(TIF)

###### 

Click here for additional data file.

###### Time-dependent differences in plasma levels of sCD62P.

Blood was anticoagulated with CTAD (black bar), citrate (dark grey bar), heparin (grey bar) or EDTA (white bar) and stored at 4°C (A-B) or at room temperature (C-D) for 0.5 h, 2 h, 6 h or 24 h until plasma preparation. Total concentrations of sCD62P (A, C) and fold concentrations in comparison to CTAD 4°C 30 min were determined for each time point. Significant differences were analyzed using two-way ANOVA with Dunnett correction (with CTAD as reference).

(TIF)

###### 

Click here for additional data file.

###### Effect of *in vitro* platelet activation on concentration of sCD62P.

Blood was anticoagulated with CTAD, citrate, heparin or EDTA (grey bar) and stimulated with the platelet activator thrombin (dark grey bar) at a submaximal dose for 0.5 h and 6 h at room temperature. Subsequently, plasma was prepared and analyzed for sCD62P (A, B) levels. Significant differences were analyzed using two-way ANOVA with Bonferroni correction.

(TIF)

###### 

Click here for additional data file.
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